Form 4: PACB CEO Sells Shares for Tax Obligations

Pacific Biosciences CEO Christian Henry sold 472,667 shares of common stock across two transactions to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Christian O. Henry, President & CEO of Pacific Biosciences of California, Inc. (PACB), reported sales of common stock.
• The sales were made to cover tax withholding obligations associated with the vesting of restricted stock units.
• A total of 331,793 shares were sold on February 17, 2026, at a weighted average price of $1.576 per share, with prices ranging from $1.51 to $1.68.
• An additional 140,874 shares were sold on February 18, 2026, at a weighted average price of $1.629 per share, with prices ranging from $1.55 to $1.70.
• Following these transactions, Mr. Henry directly beneficially owns 2,673,500 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are routine, non-discretionary transactions for tax purposes related to RSU vesting, rather than a signal of management's changing sentiment about the company's prospects.

Positives

• The sales were non-discretionary, specifically for tax withholding obligations related to RSU vesting, indicating a routine compensation event rather than a lack of confidence in the company.
• The transactions were executed under a Rule 10b5-1 plan, demonstrating pre-planned and compliant insider trading practices.

Negatives

• The CEO's direct beneficial ownership of common stock decreased by 472,667 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported sales represent the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine aspect of executive compensation. These transactions are typically non-discretionary and often pre-arranged under Rule 10b5-1 plans, distinguishing them from discretionary sales that might signal changes in management's outlook.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of selling shares to cover tax liabilities upon RSU vesting is a standard industry practice across publicly traded companies, particularly in the technology and biotechnology sectors.
• This mechanism is a common component of executive compensation packages, similar to practices seen at companies like Illumina or Thermo Fisher Scientific, where executives routinely manage equity awards through pre-scheduled tax-related sales.

Stakeholder Impact

• Shareholders: A minor reduction in the CEO's direct beneficial ownership, but the non-discretionary nature of the sale mitigates concerns about management confidence.
• Employees: No direct impact mentioned, as this relates to executive compensation.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported sales by CEO Christian Henry are non-discretionary, routine transactions to cover tax obligations associated with restricted stock unit vesting, executed under a Rule 10b5-1 plan. This type of insider sale is not typically indicative of a change in the company's fundamentals or management's long-term outlook, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

PACB, Pacific Biosciences, Christian Henry, Form 4, Insider Trading, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, Rule 10b5-1